Mariappan V. Chelliah
Merck & Co.
28 Papers
403 Citations
Mariappan V. Chelliah is an academic researcher from Merck & Co.. The author has contributed to research in topics: Himbacine & Thrombin receptor. The author has an hindex of 11, co-authored 28 publications. Previous affiliations of Mariappan V. Chelliah include Schering-Plough.
Chat about Author
Papers
Patent
Thrombin receptor antagonists
Samuel Chackalamannil,Mariappan V. Chelliah,Yan Xia +2 more
- 05 Oct 2005
TL;DR: In this article, a series of compounds represented by the structural formulas and pharmaceutically acceptable isomers, salts, solvates and polymorphs thereof are disclosed, and pharmaceutical compositions containing said compounds and their use as thrombin receptor antagonists and binders to cannabinoid receptors.
144
Patent
Nor-seco himbacine derivatives useful as thrombin receptor antagonists
Chackalamannil Samuel,Mariappan V. Chelliah,Yan Xia +2 more
- 13 Jun 2001
TL;DR: Heterocyclic-substituted compounds of the formula or a pharmaceutically acceptable salt thereof are disclosed in this article, where the authors present a solution to the problem.
43
Heterotricyclic himbacine analogs as potent, orally active thrombin receptor (protease activated receptor-1) antagonists.
Mariappan V. Chelliah,Samuel Chackalamannil,Yan Xia,Keith Eagen,Martin C. Clasby,Xiaobang Gao,William J. Greenlee,Ho-Sam Ahn,Jacqueline Agans-Fantuzzi,George Boykow,Yunsheng Hsieh,Matthew Bryant,Jairam Palamanda,Chan Tze-Ming,David Hesk,Madhu Chintala +15 more
TL;DR: A series of compounds that incorporate heteroatoms in the C-ring of the tricyclic motif are synthesized, resulting in the identification of several potent heterocyclic analogs with excellent affinity for the thrombin receptor.
34
Discovery of MK-8831, A Novel Spiro-Proline Macrocycle as a Pan-Genotypic HCV-NS3/4a Protease Inhibitor.
Santhosh Neelamkavil,Sony Agrawal,Thomas Bara,Chad Bennett,Sathesh Bhat,Dipshikha Biswas,Linda Brockunier,Nicole Buist,Duane Burnette,Mark Cartwright,Samuel Chackalamannil,Robert Chase,Mariappan V. Chelliah,Austin Chen,Martin C. Clasby,Vincent J. Colandrea,Ian W. Davies,Keith Eagen,Zhuyan Guo,Yongxin Han,John A. Howe,Charles Lee Jayne,Josien Hubert B,Stacia Kargman,Karen Marcantonio,Shouwu Miao,Randy R. Miller,Andrew Nolting,Pinto Patrick A,Murali Rajagopalan,Rebecca T. Ruck,Shah Unmesh G,Aileen Soriano,Donald M. Sperbeck,Francisco Velazquez,Jin Wu,Yan Xia,Srikanth Venkatraman +37 more
TL;DR: The rational application of structural chemistry with molecular modeling guided the design and optimization of the structure-activity relationships have resulted in the identification of the clinical candidate MK-8831 with excellent pan-genotypic activity and safety profile.
31
Patent
4, 5, 6-trisubstituted pyrimidine derivatives as factor ixa inhibitors
Mariappan V. Chelliah,Samuel Chackalamannil,William J. Greenlee,Keith Eagen,Zhuyan Guo,Martin C. Clasby,Yan Xia,Charles Lee Jayne,Michael P. Dwyer,Kartik M. Keertikar,Tin-Yau Chan,Li Wang +11 more
- 03 Aug 2010
TL;DR: In this article, novel heterocyclic compounds of Formulae (I): (Chemical formula should be inserted here as it appears on abstract in paper form) Formula (I) as disclosed herein, or a pharmaceutically acceptable salt, solvate, ester, prodrug or stereoisomer thereof.
28